Contact Us
How to Reach Us
At Scienture, the lines of communication are always open. Whether you’re a healthcare professional or pharmacist, we’re here to help.
Customer Service
Healthcare providers and pharmacists seeking customer service or additional information about REZENOPYTM can find assistance by:
Phone: 1-888-353-0221, Monday through Friday, 8:30 AM to 5:00 PM (ET)
Email: Scienture Customer Service
Request Information or a meeting: Use our form
Scienture Corporate Office
Phone: 631-670-6039
Mail: 20 Austin Boulevard
Commack, New York 11725
General inquiries: Contact Form
Website: Scienture.com
If you have a medical emergency, call 911 or your local emergency services number.
To Report an Adverse Event
To report an adverse event or product complaint, please contact us at [email protected] or call 1-833-754-4917. Adverse events may also be reported to the FDA directly at 1-800-FDA-1088 or www.fda.gov/medwatch.
Media Inquiries
To contact Scienture, LLC re: REZENOPY or media requests in general:
- Email: [email protected]
- Phone: 631-670-6039
Media Kit Assets
- REZENOPY product device image (.jpg)
- REZENOPY horizontal logo (.png)
- REZENOPY vertical logo (.png)
Brand Usage
REZENOPY Media Kit assets and Brand Guidelines are available for authorized use.
Brand Guidelines for REZENOPY™ (naloxone HCl) Nasal Spray 10 mg
This document provides standards and guidelines for the use of the REZENOPY brand and identity. These standards are to be consistently applied to all of our branded touchpoints including advertising, print, collateral, signage, website, packaging and labeling.
To request brand use approval, contact [email protected].
The brand assets, including but not limited to logos, trademarks, and other intellectual property detailed within this guide, are the sole property of Scienture, LLC and are protected under applicable intellectual property laws. Any use of our brand assets requires the express written consent of an authorized representative of Scienture, LLC. Unauthorized use of our brand assets is strictly prohibited and may result in legal action, including claims for trademark infringement.
